Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Argos Therapeutics, which is developing immunotherapies for the treatment of renal cell carcinoma and HIV, raised $45 million by offering 5.625 million shares (all primary) at $8. The company had originally filed to sell 4.25 million shares at a range of $13 to...read more
Large deals from Santander Consumer USA (SC) and Rice Energy (RICE) posted pedestrian returns last week, while Care.com (CRCM) had the first substantial IPO pop of the year, jumping 43%. The site lifted the year’s average IPO return from 4% to a...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Argos Therapeutics prices IPO below the range at $8, raising $45 million
Argos Therapeutics, which is developing immunotherapies for the treatment of renal cell carcinoma and HIV, raised $45 million by offering 5.625 million shares (all primary) at $8. The company had originally filed to sell 4.25 million shares at a range of $13 to...read more
12 US IPOs planned for the week of Feb 3
The following IPOs are expected to price this week: Argos Therapeutics (ARGS), which is developing immunotherapies for the treatment of cancer and HIV, plans to raise...read more
US IPO Recap: Care.com tends to a slow-starting IPO market
Large deals from Santander Consumer USA (SC) and Rice Energy (RICE) posted pedestrian returns last week, while Care.com (CRCM) had the first substantial IPO pop of the year, jumping 43%. The site lifted the year’s average IPO return from 4% to a...read more